Search This Blog

Wednesday, 11 January 2017

Diabetes, hepatitis drugs new bestsellers



In perhaps a grim reminder of the alarming spread of lifestyle diseases, medicines to treat hepatitis C virus (sofosbuvir) and diabetes (teneligliptin) have emerged as the largest selling drugs in 2016 among the new launches in the domestic retail market.
Hepatitis C (a liver infection) medicines and combinations dominated the top 10 brands launched over the two-year period, with Natco Pharma's Hepcinat (sofosbuvir) netting sales of Rs 158 crore, followed closely by Sun Pharma's Revital H, a health supplement, with Rs 148 crore, data cul led from market research firm AIOCD Awacs showed (see chart inside).
Overall, the market, whi ch is valued at Rs 1.07 lakh crore, showed a robust growth of over 10% for the year, buoyed by strong sales of anti-diabetic and cardiac therapies. In fact, showing the domi nance of anti-diabetic drugs in the pharma market, diabetes therapy Mixtard from Novo Nordisk has become the first brand to cross Rs 500 crore in sales, while Sun Pharma, Abbott and Cipla retained their slots as top companies in the domestic retail market for 12month period ending December 2016.
Dr Anoop Misra, chairman, Fortis Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology , said: “It is unfortunate that diabetes and Hep C-related liver diseases continue to rise unabated, requiring increased sustenance on medications, ultimately draining the health, economy and productivity of the country.“ Mirroring the rise of these diseases, nearly 10 sofosbuvir brands have been launched, while teneligliptin medicines are dominating the anti-diabetic space. Overall, anti-infectives, cardiac and gastrointestinal medicines make up nearly 40% of the market, with sales of anti-diabetics adding the largest incremental value of Rs 1,427 crore during the 12-month period ending December 2016.
Anti-diabetic drugs show largest growth of Rs 1.4k cr
In perhaps a grim reminder of the alarming spread of lifestyle diseases, medicines to treat hepatitis C virus (sofosbuvir) and diabetes (teneligliptin) have emerged as the largest selling drugs in 2016 among the new launches in the domestic retail market.
Hepatitis C (a liver infection) medicines and combinations dominated the top 10 brands launched over the two-year period, with Natco Pharma's Hepcinat (sofosbuvir) netting sales of Rs 158 crore, followed closely by Sun Pharma's Revital H, a health supplement, with Rs 148 crore, data cul led from market research firm AIOCD Awacs showed (see chart inside).
Overall, the market, whi ch is valued at Rs 1.07 lakh crore, showed a robust growth of over 10% for the year, buoyed by strong sales of anti-diabetic and cardiac therapies. In fact, showing the domi nance of anti-diabetic drugs in the pharma market, diabetes therapy Mixtard from Novo Nordisk has become the first brand to cross Rs 500 crore in sales, while Sun Pharma, Abbott and Cipla retained their slots as top companies in the domestic retail market for 12month period ending December 2016.
Dr Anoop Misra, chairman, Fortis Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology , said: “It is unfortunate that diabetes and Hep C-related liver diseases continue to rise unabated, requiring increased sustenance on medications, ultimately draining the health, economy and productivity of the country.“ Mirroring the rise of these diseases, nearly 10 sofosbuvir brands have been launched, while teneligliptin medicines are dominating the anti-diabetic space. Overall, anti-infectives, cardiac and gastrointestinal medicines make up nearly 40% of the market, with sales of anti-diabetics adding the largest incremental value of Rs 1,427 crore during the 12-month period ending December 2016.
 Source: TIMES OF INDIA-10th January,2017